Tags

Type your tag names separated by a space and hit enter

Orlistat increases serum paraoxonase activity in obese patients.
Nutr Metab Cardiovasc Dis. 2007 May; 17(4):268-73.NM

Abstract

BACKGROUND AND AIM

Previous studies have demonstrated that oxidative stress is increased in obese patients. The high-density lipoprotein (HDL) associated human paraoxonase 1 (PON1) can inhibit low-density lipoprotein oxidation and has an antiatherogenic effect. Our objective was to assess the effects of orlistat therapy combined with diet on body mass index (BMI), waist circumference, lipid parameters, blood pressure, serum glucose level and PON1 activity.

METHODS AND RESULTS

A longitudinal, multicenter, randomized study with and without orlistat treatment was performed. One hundred thirty nine otherwise healthy, obese subjects were divided in to two groups: 78 persons received orlistat (120 mg three times a day) combined with diet while 61 persons were kept on diet only. Anthropometrical parameters, serum lipid levels and PON1 activity were measured at baseline and after 6 months of treatment. BMI and waist circumference were reduced more pronouncedly in the orlistat group than in the control group. Patients receiving orlistat also had significantly greater improvements in fasting blood glucose levels and blood pressure. The orlistat-treated group showed a greater reduction in total cholesterol and triglyceride levels. In addition, the serum PON1 activity in these patients was significantly increased compared to the diet-only group.

CONCLUSIONS

The 6-month treatment with orlistat had a beneficial effect on the lipid profile and improved the antioxidant status by increasing serum PON1 activity. However, because of the limited therapeutic effectiveness, obese patients with hypercholesterolemia should receive additional lipid lowering medications.

Authors+Show Affiliations

Department of Metabolic Medicine, St. Imre Hospital, Budapest, Hungary.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17134960

Citation

Audikovszky, Mária, et al. "Orlistat Increases Serum Paraoxonase Activity in Obese Patients." Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, vol. 17, no. 4, 2007, pp. 268-73.
Audikovszky M, Pados G, Seres I, et al. Orlistat increases serum paraoxonase activity in obese patients. Nutr Metab Cardiovasc Dis. 2007;17(4):268-73.
Audikovszky, M., Pados, G., Seres, I., Harangi, M., Fülöp, P., Katona, E., Illyés, L., Winkler, G., Katona, E. M., & Paragh, G. (2007). Orlistat increases serum paraoxonase activity in obese patients. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, 17(4), 268-73.
Audikovszky M, et al. Orlistat Increases Serum Paraoxonase Activity in Obese Patients. Nutr Metab Cardiovasc Dis. 2007;17(4):268-73. PubMed PMID: 17134960.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Orlistat increases serum paraoxonase activity in obese patients. AU - Audikovszky,Mária, AU - Pados,Gyula, AU - Seres,Ildikó, AU - Harangi,Mariann, AU - Fülöp,Péter, AU - Katona,Evelin, AU - Illyés,László, AU - Winkler,Gábor, AU - Katona,Eva M, AU - Paragh,György, Y1 - 2006/07/10/ PY - 2005/07/21/received PY - 2006/03/21/accepted PY - 2006/12/1/pubmed PY - 2007/5/12/medline PY - 2006/12/1/entrez SP - 268 EP - 73 JF - Nutrition, metabolism, and cardiovascular diseases : NMCD JO - Nutr Metab Cardiovasc Dis VL - 17 IS - 4 N2 - BACKGROUND AND AIM: Previous studies have demonstrated that oxidative stress is increased in obese patients. The high-density lipoprotein (HDL) associated human paraoxonase 1 (PON1) can inhibit low-density lipoprotein oxidation and has an antiatherogenic effect. Our objective was to assess the effects of orlistat therapy combined with diet on body mass index (BMI), waist circumference, lipid parameters, blood pressure, serum glucose level and PON1 activity. METHODS AND RESULTS: A longitudinal, multicenter, randomized study with and without orlistat treatment was performed. One hundred thirty nine otherwise healthy, obese subjects were divided in to two groups: 78 persons received orlistat (120 mg three times a day) combined with diet while 61 persons were kept on diet only. Anthropometrical parameters, serum lipid levels and PON1 activity were measured at baseline and after 6 months of treatment. BMI and waist circumference were reduced more pronouncedly in the orlistat group than in the control group. Patients receiving orlistat also had significantly greater improvements in fasting blood glucose levels and blood pressure. The orlistat-treated group showed a greater reduction in total cholesterol and triglyceride levels. In addition, the serum PON1 activity in these patients was significantly increased compared to the diet-only group. CONCLUSIONS: The 6-month treatment with orlistat had a beneficial effect on the lipid profile and improved the antioxidant status by increasing serum PON1 activity. However, because of the limited therapeutic effectiveness, obese patients with hypercholesterolemia should receive additional lipid lowering medications. SN - 1590-3729 UR - https://www.unboundmedicine.com/medline/citation/17134960/Orlistat_increases_serum_paraoxonase_activity_in_obese_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0939-4753(06)00096-2 DB - PRIME DP - Unbound Medicine ER -